- Home
- EDAP vs AGEN Comparison
EDAP vs AGEN Comparison
Compare EDAP & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDAP
- AGEN
- Stock Information
- Founded
- EDAP 1979
- AGEN 1994
- Country
- EDAP France
- AGEN United States
- Employees
- EDAP N/A
- AGEN N/A
- Industry
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EDAP Health Care
- AGEN Health Care
- Exchange
- EDAP Nasdaq
- AGEN Nasdaq
- Market Cap
- EDAP 81.6M
- AGEN 96.2M
- IPO Year
- EDAP 1997
- AGEN 2000
- Fundamental
- Price
- EDAP $2.36
- AGEN $2.99
- Analyst Decision
- EDAP Strong Buy
- AGEN Buy
- Analyst Count
- EDAP 1
- AGEN 3
- Target Price
- EDAP $19.00
- AGEN $10.50
- AVG Volume (30 Days)
- EDAP 230.9K
- AGEN 551.7K
- Earning Date
- EDAP 11-07-2024
- AGEN 11-12-2024
- Dividend Yield
- EDAP N/A
- AGEN N/A
- EPS Growth
- EDAP N/A
- AGEN N/A
- EPS
- EDAP N/A
- AGEN N/A
- Revenue
- EDAP $70,722,730.00
- AGEN $160,427,000.00
- Revenue This Year
- EDAP $6.96
- AGEN N/A
- Revenue Next Year
- EDAP $15.53
- AGEN $36.13
- P/E Ratio
- EDAP N/A
- AGEN N/A
- Revenue Growth
- EDAP 12.17
- AGEN 59.00
- 52 Week Low
- EDAP $2.14
- AGEN $2.50
- 52 Week High
- EDAP $8.50
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- EDAP 45.48
- AGEN 41.32
- Support Level
- EDAP $2.14
- AGEN $2.73
- Resistance Level
- EDAP $2.47
- AGEN $3.85
- Average True Range (ATR)
- EDAP 0.15
- AGEN 0.29
- MACD
- EDAP 0.02
- AGEN -0.01
- Stochastic Oscillator
- EDAP 33.96
- AGEN 24.03
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).